肝豆状核变性的中西医结合治疗

古玉梅; 黄叶青; 张蓓; 刘爱群; 彭忠兴; 洪铭范; 周志华

doi:10.12449/JCH260306

肝豆状核变性的中西医结合治疗

DOI: 10.12449/JCH260306

1.
广东药科大学附属第一医院神经内科，广州 510000
2.
广东药科大学附属第一医院阳江医院（江城区人民医院）神经内科，广东阳江 529500

基金项目:

广东省中医药局科研项目 (20251220);

广东省医学科研基金 (B2025155);

广东省研究生教育创新计划项目 (2025ANLK_049)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：古玉梅负责文献检索，初稿撰写，修订定稿；黄叶青、张蓓、刘爱群、彭忠兴协助文献收集与分析；洪铭范给予学术指导，审阅和修改论文；周志华设计研究框架，审阅论文并最终定稿。

详细信息

通信作者:
周志华， zhouzh20051103@163.com （ORCID： 0000-0001-6262-6365）

计量
- 文章访问数: 7
- HTML全文浏览量: 2
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2026-01-04
- 录用日期: 2026-02-03
- 出版日期: 2026-03-25

Integrated traditional Chinese and Western medicine therapy for Wilson disease

1.
Department of Neurology，The First Affiliated Hospital of Guangdong Pharmaceutical University，Guangzhou 510000，China
2.
Department of Neurology，Yangjiang Hospital of The First Affiliated Hospital of Guangdong Pharmaceutical University （Jiangcheng District People’s Hospital），Yangjiang，Guangdong 529500，China

Research funding:

Scientific Research Project of Guangdong Provincial Administration of Traditional Chinese Medicine (20251220);

Guangdong Medical Scientific Research Foundation (B2025155);

Guangdong Postgraduate Education Innovation Program (2025ANLK_049)

More Information

Corresponding author: ZHOU Zhihua， zhouzh20051103@163.com （ORCID： 0000-0001-6262-6365）

摘要

摘要: 肝豆状核变性是少数可治疗的神经遗传性疾病之一。目前，肝豆状核变性的治疗仍以西药为主，但20世纪90年代以来，杨任民教授团队的多项研究显示中医药亦具有良好疗效。本文在肝豆状核变性低铜饮食原则的基础上，系统阐述了西医治疗（药物、肝移植和脾切除）的利弊及注意事项，综述了国内代表性的中医药研究成果，特别是临床广泛使用的肝豆汤，研究表明，其能有效改善患者的神经系统症状、保护肝肾功能，且避免了金属螯合剂的潜在药物不良反应，可作为肝豆状核变性长期辅助治疗的有效选择。须强调，肝豆状核变性中西医结合治疗应注重病症结合，避免使用含铜量高的中药，以防加重病情。
- 肝豆状核变性 /
- 饮食疗法 /
- 中西医结合疗法
Abstract: Wilson disease （WD） is one of the few treatable neurogenetic disorders. Currently， Western medicine remains the main treatment method for WD， while since the 1990s， multiple studies conducted by Professor Yang Renmin and his team have shown that traditional Chinese medicine （TCM） also has a favorable therapeutic effect. Based on the principle of low-copper diet for WD， this article systematically elaborates on the advantages， limitations， and key considerations of current Western medicine therapies （pharmacotherapy， liver transplantation， and splenectomy） and reviews the research findings of TCM in China， especially the wide application of Gandou Decoction in clinical practice. Studies have shown that Gandou Decoction can effectively improve neurological symptoms， protect hepatic and renal function， and avoid the adverse drug reactions associated with metal chelating agents， and therefore， it can be used an effective long-term adjuvant therapy for WD. It should be noted that symptoms and signs should be considered in integrated traditional Chinese and Western medicine therapy for WD， and high-copper TCM drugs should be avoided to prevent deterioration.
- Hepatolenticular Degeneration /
- Dietary Therapy /
- Integrated Chinese Traditional and Western Medicine Therapy

HTML全文

参考文献(47)

[1]	KINNIER WILSON SA. Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver[J]. Lancet, 1912, 179( 4626): 1115- 1119. DOI: 10.1016/S0140-6736(01)67414-2.
[2]	Parkinson Disease and Movement Disorders Group of the Neurology Branch of the Chinese Medical Association, Neurogenetic Diseases Group of the Neurology Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of Wilson’s disease[J]. Chin J Neurol, 2008, 41( 8): 566- 569. DOI: 10.3321/j.issn:1006-7876.2008.08.022. 中华医学会神经病学分会帕金森病及运动障碍学组, 中华医学会神经病学分会神经遗传病学组. 肝豆状核变性的诊断与治疗指南[J]. 中华神经科杂志, 2008, 41( 8): 566- 569. DOI: 10.3321/j.issn:1006-7876.2008.08.022.
[3]	Chinese Society of Neurogenetics. Chinese guidelines for diagnosis and treatment of Wilson’s disease 2021[J]. Chin J Neurol, 2021, 54( 4): 310- 319. DOI: 10.3760/cma.j.cn113694-20200826-00661. 中华医学会神经病学分会神经遗传学组. 中国肝豆状核变性诊治指南2021[J]. 中华神经科杂志, 2021, 54( 4): 310- 319. DOI: 10.3760/cma.j.cn113694-20200826-00661.
[4]	Inherited Metabolic Liver Disease Collaboration Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the diagnosis and treatment of hepatolenticular degeneration(2022 edition)[J]. Chin J Hepatol, 2022, 30( 1): 9- 20. DOI: 10.3760/cma.j.cn501113-20211217-00603. 中华医学会肝病学分会遗传代谢性肝病协作组. 肝豆状核变性诊疗指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30( 1): 9- 20. DOI: 10.3760/cma.j.cn501113-20211217-00603.
[5]	ROBERTS EA, SCHILSKY ML. Diagnosis and treatment of Wilson disease: An update[J]. Hepatology, 2008, 47( 6): 2089- 2111. DOI: 10.1002/hep.22261.
[6]	SCHILSKY ML, ROBERTS EA, BRONSTEIN JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases[J]. Hepatology, 2025, 82( 3): E41- E90. DOI: 10.1002/hep.32801.
[7]	European Association for Study of Liver. EASL clinical practice guidelines: Wilson’s disease[J]. J Hepatol, 2012, 56( 3): 671- 685. DOI: 10.1016/j.jhep.2011.11.007.
[8]	European Association for the Study of the Liver. EASL-ERN clinical practice guidelines on Wilson’s disease[J]. J Hepatol, 2025, 82( 4): 690- 728. DOI: 10.1016/j.jhep.2024.11.007.
[9]	LI WJ, CHEN C, YOU ZF, et al. Current drug managements of Wilson’s disease: From west to east[J]. Curr Neuropharmacol, 2016, 14( 4): 322- 325. DOI: 10.2174/1570159x14666151130222427.
[10]	YANG RM, FENG T, CAI W, et al. Chinese multidisciplinary expert consensus on orphan/anticopper drugs and other non-drug management of hepatolenticular degeneration[J]. Curr Neuropharmacol, 2025, 23( 13): 1683- 1708. DOI: 10.2174/011570159X349587250311072553.
[11]	CHEN H, WANG X, TANG L, et al. Review of the efficacy and mechanisms of traditional Chinese medicine for treating multi-organ damage in Wilson’s disease[J]. Drug Des Devel Ther, 2025, 19: 2453- 2471. DOI: 10.2147/DDDT.S515123.
[12]	PENG CL, LI W, JIANG HS, et al. Characterization of nerve biopsy in copper deficiency peripheral neuropathy due to over-treatment of Wilson’s disease: A case report[J]. Acta Neurol Belg, 2025, 125( 2): 579- 582. DOI: 10.1007/s13760-025-02762-7.
[13]	WEISS KH, GOTTHARDT DN, KLEMM D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease[J]. Gastroenterology, 2011, 140( 4): 1189- 1198. DOI: 10.1053/j.gastro.2010.12.034.
[14]	LITWIN T, ANTOS A, BEMBENEK J, et al. Copper deficiency as Wilson’s disease overtreatment: A systematic review[J]. Diagnostics, 2023, 13( 14): 2424. DOI: 10.3390/diagnostics13142424.
[15]	CAI S, GONG JY, YANG J, et al. Anemia following zinc treatment for Wilson’s disease: A case report and literature review[J]. BMC Gastroenterol, 2019, 19( 1): 120. DOI: 10.1186/s12876-019-1038-5.
[16]	WU LM, EKLADIOUS A, WHEELER L, et al. Wilson disease: Copper deficiency and iatrogenic neurological complications with zinc therapy[J]. Intern Med J, 2020, 50( 1): 121- 123. DOI: 10.1111/imj.14694.
[17]	KIRK FT, MUNK DE, SWENSON ES, et al. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease[J]. J Hepatol, 2024, 80( 4): 586- 595. DOI: 10.1016/j.jhep.2023.11.023.
[18]	WALSHE JM. The story of penicillamine: A difficult birth[J]. Mov Disord, 2003, 18( 8): 853- 859. DOI: 10.1002/mds.10458.
[19]	LITWIN T, ANTOS A, BEMBENEK J, et al. Neurological deterioration in Wilson’s disease-types, etiology, course, and management[J]. Discov Med, 2024, 36( 183): 646- 654. DOI: 10.24976/Discov.Med.202436183.61.
[20]	BREWER GJ, TERRY CA, AISEN AM, et al. Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy[J]. Arch Neurol, 1987, 44( 5): 490- 493. DOI: 10.1001/archneur.1987.00520170020016.
[21]	KLEINIG TJ, HARLEY H, THOMPSON PD. Neurological deterioration during treatment in Wilson’s disease: Question[J]. J Clin Neurosci, 2008, 15( 5): 575, 607. DOI: 10.1016/j.jocn.2007.03.001.
[22]	KALITA J, KUMAR V, CHANDRA S, et al. Worsening of Wilson disease following penicillamine therapy[J]. Eur Neurol, 2014, 71( 3-4): 126- 131. DOI: 10.1159/000355276.
[23]	RANJAN A, KALITA J, KUMAR V, et al. MRI and oxidative stress markers in neurological worsening of Wilson disease following penicillamine[J]. Neurotoxicology, 2015, 49: 45- 49. DOI: 10.1016/j.neuro.2015.05.004.
[24]	ZHOU ZH, WU YF, YAN Y, et al. Persistence with medical treatment for Wilson disease in China based on a single center’s survey research[J]. Brain Behav, 2021, 11( 6): e02168. DOI: 10.1002/brb3.2168.
[25]	YANG RM. Wilson disease[M]. Beijing: People’s Medical Publishing House, 2015. 杨任民. 肝豆状核变性[M]. 北京: 人民卫生出版社, 2015.
[26]	ZHOU XX, LI XH, HUANG HW, et al. Study on the method and curative effect of sodium dimercaptopropane sulfonate combined with zinc agent in the treatment of hepatolenticular degeneration[J]. J Pract Med, 2010, 26( 23): 4393- 4396. DOI: 10.3969/j.issn.1006-5725.2010.23.059. 周香雪, 李洵桦, 黄海威, 等. 二巯基丙磺钠结合锌剂治疗肝豆状核变性方法及疗效研究[J]. 实用医学杂志, 2010, 26( 23): 4393- 4396. DOI: 10.3969/j.issn.1006-5725.2010.23.059.
[27]	GAO YN, ZHANG J, TANG LL, et al. DMPS-induced neurological deterioration in neurological Wilson’s disease patients: A retrospective case-control study on clinical characteristics and risk factors[J]. Front Neurol, 2025, 16: 1599209. DOI: 10.3389/fneur.2025.1599209.
[28]	SCHILSKY ML, CZLONKOWSKA A, ZUIN M, et al. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease(CHELATE): A randomised, open-label, non-inferiority, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7( 12): 1092- 1102. DOI: 10.1016/S2468-1253(22)00270-9.
[29]	KIM B, CHUNG SJ, SHIN HW. Trientine-induced neurological deterioration in a patient with Wilson’s disease[J]. J Clin Neurosci, 2013, 20( 4): 606- 608. DOI: 10.1016/j.jocn.2012.02.041.
[30]	ARNON R, ANNUNZIATO R, SCHILSKY M, et al. Liver transplantation for children with Wilson disease: Comparison of outcomes between children and adults[J]. Clin Transplant, 2011, 25( 1): E52- E60. DOI: 10.1111/j.1399-0012.2010.01327.x.
[31]	WANG A, BAKIR N, NGO C, et al. Postoperative outcomes following liver transplantation for Wilson’s disease: A systematic review and meta-analysis[J]. Clin Transplant, 2025, 39( 6): e70155. DOI: 10.1111/ctr.70155.
[32]	FANG WY, WANG JS. An excerpt of EASL-ERN clinical practice guidelines on Wilson’s disease(2025 edition)[J]. J Clin Hepatol, 2025, 41( 5): 839- 843. DOI: 10.12449/JCH250507. 方微园, 王建设.《2025年欧洲肝病学会/欧洲罕见病网络临床实践指南: 肝豆状核变性》摘译[J]. 临床肝胆病杂志, 2025, 41( 5): 839- 843. DOI: 10.12449/JCH250507.
[33]	ZHENG Z, YU QS, PAN JF, et al. Effect of hepatolenticular degeneration combined with hypersplenism after splenectomy[J]. Clin J Tradit Chin Med, 2020, 32( 5): 947- 951. DOI: 10.16448/j.cjtcm.2020.0536. 郑州, 于庆生, 潘晋方, 等. 肝豆状核变性合并脾功能亢进脾切除近期疗效[J]. 中医药临床杂志, 2020, 32( 5): 947- 951. DOI: 10.16448/j.cjtcm.2020.0536.
[34]	XING WF, ZHOU ZH, HUANG YQ, et al. Comparison of curative effect between partial splenic embolization and splenectomy for hepatolenticular degeneration with hypersplenism[J]. J Pract Med, 2019, 35( 21): 3333- 3337, 3342. DOI: 10.3969/j.issn.1006-5725.2019.21.014. 幸伟芳, 周志华, 黄叶青, 等. 部分脾动脉栓塞术与脾切除术治疗肝豆状核变性合并脾亢的疗效比较[J]. 实用医学杂志, 2019, 35( 21): 3333- 3337, 3342. DOI: 10.3969/j.issn.1006-5725.2019.21.014.
[35]	HONG MF, HU JY, HU WB, et al. Syndrome differentiation and classification of hepatolenticular degeneration in traditional Chinese medicine[J]. J Anhui Tradit Chin Med Coll, 1998, 17( 1): 10- 11. 洪铭范, 胡纪原, 胡文彬, 等. 肝豆状核变性的中医辨证分型[J]. 安徽中医学院学报, 1998, 17( 1): 10- 11.
[36]	YANG RM, HAN YZ, REN MS, et al. 107 cases of hepatolenticular degeneration treated by traditional Chinese medicine[J]. J Tradit Chin Med, 1993, 34( 11): 676- 677, 644. DOI: 10.13288/j.11-2166/r.1993.11.024. 杨任民, 韩咏竹, 任明山, 等. 中药治疗肝豆状核变性107例疗效观察[J]. 中医杂志, 1993, 34( 11): 676- 677, 644. DOI: 10.13288/j.11-2166/r.1993.11.024.
[37]	YANG RM, BAO YC, YANG XT, et al. Observation on copper excretion of 37 cases of Wilson’s disease treated with“anti-hepatolenticular degeneration decoction”[J]. Chin J Integr Tradit West Med, 1984, 4( 8): 462- 464, 450. 杨任民, 鲍远程, 杨兴涛, 等. 肝豆汤对37例肝豆状核变性驱铜的观察[J]. 中西医结合杂志, 1984, 4( 8): 462- 464, 450.
[38]	WANG X, HAN YZ, YANG RM. Overview of traditional Chinese and western medicine treatments on hepatolenticular degeneration[J]. J Intern Med Concepts Pract, 2021, 16( 5): 294- 298. DOI: 10.16138/j.1673-6087.2021.05.002. 王训, 韩咏竹, 杨任民. 肝豆状核变性的中西医药物治疗概况[J]. 内科理论与实践, 2021, 16( 5): 294- 298. DOI: 10.16138/j.1673-6087.2021.05.002.
[39]	HU WB, YANG RM. Effect of Gandou Tablet I on trace elements excretion in patients with hepatolenticular degeneration[J]. Chin J Clin Rehabil, 2003, 7( 30): 4165. DOI: 10.3321/j.issn: 1673-8225.2003.30.054. 胡文彬, 杨任民. 肝豆片Ⅰ号对肝豆状核变性患者微量元素排泄的影响[J]. 中国临床康复, 2003, 7( 30): 4165. DOI: 10.3321/j.issn:1673-8225.2003.30.054.
[40]	HAN YZ, HE GY, WANG X, et al. Comparative study on therapeutic effects of Gandou Tablet I and dimercaptosuccinate acid in treating Wilson disease[J]. Chin J Integr Tradit West Med, 1999, 19( 2): 69- 70. DOI: 10.3321/j.issn:1003-5370.1999.02.002. 韩咏竹, 何光远, 王训, 等. 中药肝豆片Ⅰ号与二巯基丁二酸治疗肝豆状核变性疗效的比较[J]. 中国中西医结合杂志, 1999, 19( 2): 69- 70. DOI: 10.3321/j.issn:1003-5370.1999.02.002.
[41]	XUE BC, YANG RM, HU JY, et al. Effect of Gandou Decoction IV combined with short-term decoppering therapy with sodium dimercapto sulphonate on serum indexes of hepatic fibrosis in patients with Wilson’s disease[J]. Chin J Integr Tradit West Med, 2007, 27( 9): 785- 788. DOI: 10.3321/j.issn: 1003-5370.2007.09.006. 薛本春, 杨任民, 胡纪源, 等. 肝豆汤Ⅳ号联合短期驱铜治疗对肝豆状核变性患者肝纤维化血清学指标的影响[J]. 中国中西医结合杂志, 2007, 27( 9): 785- 788. DOI: 10.3321/j.issn: 1003-5370.2007.09.006.
[42]	XU ZJ, WANG YX, HOU ZF, et al. Effect of Gandouling Decoction combined with sodium dimercaptopropanesulfonate on sleep disorders in Wilson’s disease patients with syndrome of combined phlegm and stasis[J]. Chin J Exp Tradit Med Formulae, 2025, 31( 14): 122- 128. DOI: 10.13422/j.cnki.syfjx.20251899. 许珍晶, 王艳昕, 侯志峰, 等. 肝豆灵汤联合二巯基丙磺酸钠治疗对痰瘀互结型Wlison病患者睡眠障碍的影响[J]. 中国实验方剂学杂志, 2025, 31( 14): 122- 128. DOI: 10.13422/j.cnki.syfjx.20251899.
[43]	SHI Q, WANG MX, QIAN NN, et al. Clinical efficacy of Gandou Fumu Decoction combined with swallowing training on Wilson’s disease with dysphagia[J]. J Nanjing Univ Tradit Chin Med, 2025, 41( 1): 115- 121. DOI: 10.14148/j.issn.1672-0482.2025.0115. 石桥, 汪美霞, 钱南南, 等. 肝豆扶木汤联合吞咽训练对Wilson病吞咽障碍的疗效观察[J]. 南京中医药大学学报, 2025, 41( 1): 115- 121. DOI: 10.14148/j.issn.1672-0482.2025.0115.
[44]	ZHAO CL, YU GF, TIAN LW, et al. Effects of Gandou Fumu Decoction on hepatic fibrosis, iron metabolism, and ferroptosis in patients with hepatolenticular degeneration[J]. J Beijing Univ Tradit Chin Med, 2025, 48( 5): 625- 635. DOI: 10.3969/j.issn.1006-2157.2025.05.005. 赵晨玲, 余郭芳, 田丽伟, 等. 肝豆扶木汤对肝豆状核变性患者肝纤维化、铁代谢及铁死亡的影响[J]. 北京中医药大学学报, 2025, 48( 5): 625- 635. DOI: 10.3969/j.issn.1006-2157.2025.05.005.
[45]	CHEN ML, XIAO HL, WANG Q, et al. Meta-analysis of the curative effect of Gandou Decoction in the treatment of hepatolenticular degeneration[J]. J Shandong First Med Univ Shandong Acad Med Sci, 2021, 42( 8): 573- 578. DOI: 10.3969/j.issn.2097-0005.2021.08.003. 陈美玲, 肖洪玲, 王倩, 等. 肝豆汤治疗肝豆状核变性疗效的Meta分析[J]. 山东第一医科大学(山东省医学科学院)学报, 2021, 42( 8): 573- 578. DOI: 10.3969/j.issn.2097-0005.2021.08.003.
[46]	Neurology Committee of Chinese Association of Integrative Medicine, YANG WM, WANG H, et al. Chinese expert consensus on integrated Chinese and western medicine management of Wilson disease-related renal damage[J]. Chin J Exp Tradit Med Formulae, 2025, 31( 19): 43- 53. DOI: 10.13422/j.cnki.syfjx.20252091. 中国中西医结合学会神经科专业委员会, 杨文明, 汪瀚, 等. 中国肝豆状核变性肾脏损害中西医结合管理专家共识[J]. 中国实验方剂学杂志, 2025, 31( 19): 43- 53. DOI: 10.13422/j.cnki.syfjx.20252091.
[47]	CHENG N, HAN YZ, YANG RM. Research progress of therapeutic mechanism of Gandou Decoction in treatment of Wilson’s disease[J]. Chin J Exp Tradit Med Formulae, 2019, 25( 7): 49- 55. DOI: 10.13422/j.cnki.syfjx.20190707. 程楠, 韩咏竹, 杨任民. 中药肝豆汤治疗Wilson病疗效机制的研究进展[J]. 中国实验方剂学杂志, 2019, 25( 7): 49- 55. DOI: 10.13422/j.cnki.syfjx.20190707.